Goldman Sachs Group Inc Biovie Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$0.4 - $0.56 $24,626 - $34,476
61,565 New
61,565 $24,000
Q1 2023

May 14, 2024
BUY
$4.89 - $10.53 $117,883 - $253,846
24,107 New
24,107 $194,000
Q1 2023

May 11, 2023
BUY
$4.89 - $10.53 $117,883 - $253,846
24,107 New
24,107 $194,000

About BIOVIE INC.

BIVI Quotes by TradingView
  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $26.5M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email